STACEY SPEARS: Open Payments
NPI 1245670314 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,182 in 63 payments from 24 companies in 2025. Trend: 2023 $1,961 · 2024 $1,644 · 2025 $1,182
Food & beverage: $1,182
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $167 |
| Merck Sharp & Dohme LLC | 8 | $163 |
| AstraZeneca Pharmaceuticals LP | 4 | $94 |
| Janssen Biotech, Inc. | 4 | $89 |
| Exelixis Inc. | 4 | $72 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Genentech USA, Inc. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Lilly USA, LLC | 2 | $44 |
Products named: KEYTRUDA, KISQALI, CABOMETYX, Enhertu, TALVEY, Polivy, IMFINZI, VERZENIO.
Industry payments across LA — which companies pay providers there.
